Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer

Cancer Research

Volumn 69, Issue 2, 2009, Pages 640-646

  Hofer, Matthias D ^a,b   Kuefer, Rainer ^c   Maier, Christiane ^c   Herkommer, Kathleen ^c   Perner, Sven ^c,d   Demichelis, Francesca ^d   Paiss, Thomas ^c   Vogel, Walter ^c   Rubin, Mark A ^d   Hoegel, Josef ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GENE PRODUCT; HYBRID PROTEIN; TMPRSS2 ERG HYBRID PROTEIN; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; FAMILIAL CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN ANALYSIS; RECURRENCE RISK; RISK FACTOR; TISSUE MICROARRAY; X CHROMOSOME;

AGED; CHROMOSOMES, HUMAN, PAIR 21; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LINKAGE (GENETICS); MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS;

EID: 58349103132     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2008     Document Type: Article

References (38)

1. Kalish LA, McDougal WS, McKinlay JB. Family history and the risk of prostate cancer. Urology 2000;56:803-6.
2. Gudmundsson J, Sulem P, Manolescu A, et al. Genomewide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39:631-7.
3. Wang L, McDonnell SK, Slusser JP, et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007;67:2944-50.
4. Lange EM, Gillanders EM, Davis CC, et al. Genomewide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate 2003;57:326-34.
5. Xu J, Gillanders EM, Isaacs SD, et al. Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate 2003;57:320-5.
6. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
7. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-41.
8. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007;26:2667-73.
9. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-8.
10. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-88.
11. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007;17:1033-6.
12. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-5.
13. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-51.
14. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008;21:1451-60.
15. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-63.
16. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9.
17. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008;8:230.
18. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993;150:797-802.
19. Maier C, Herkommer K, Hoegel J, Vogel W, Paiss T. A genomewide linkage analysis for prostate cancer susceptibility genes in families from Germany. Eur J Hum Genet 2005;13:352-60.
20. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26:312-9.
21. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006;45:717-9.
22. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 1996;58:1347-63.
23. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-4.
24. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995;11:241-7.
25. Terwilliger JD, Speer M, Ott J. Chromosome-based method for rapid computer simulation in human genetic linkage analysis. Genet Epidemiol 1993;10:217-24.
26. Westfall PH, Zaykin DV, Young SS. Multiple tests for genetic effects in association studies. Methods Mol Biol 2002;184:143-68.
27. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 1990;46:222-8.
28. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21:67-75.
29. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007;20:467-73.
30. Rouzier C, Haudebourg J, Carpentier X, et al. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet 2008;183:21-7.
31. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007;20:921-8.
32. Hofer MD, Kuefer R, Huang W, et al. Prognostic factors in lymph node-positive prostate cancer. Urology 2006;67:1016-21.
33. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007;70:630-3.
34. Mosquera JM, Perner S, Demichelis F, et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 2007;212:91-101.
35. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-43.
36. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2: ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008;14:3395-400.
37. Edwards S, Meitz J, Eles R, et al. Results of a genomewide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. Prostate 2003;57:270-9.
38. Heikkinen K, Rapakko K, Karppinen SM, et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006;27:1593-9.